Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118879 | 1.00 | KDM4E (0.31) | KDM4EMAPTNPC1HSP90AA1RAB9A | |
| SCHEMBL18716811 | 1.00 | KDM4E (0.31) | KDM4EMAPTNPC1HSP90AA1RAB9A | |
| SCHEMBL18607179 | 1.00 | KDM4E (0.31) | KDM4EMAPTNPC1HSP90AA1RAB9A | |
| SCHEMBL20118880 | 0.90 | KDM4E (0.32) | KDM4EMAPTNPC1HSP90AA1RAB9A | |
| SCHEMBL15146246 | 0.76 | KMT2A (0.37) | KDM4ESMN1; SMN2LMNAALDH1A1MEN1 | |
| SCHEMBL18358559 | 0.73 | ALDH1A1 (0.33) | KDM4EMAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL12634761 | 0.72 | TLR4 (0.41) | KDM4EMAPTRAB9ALMNAALDH1A1 | |
| SCHEMBL20111176 | 0.72 | MEN1 (0.39) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20111182 | 0.72 | ALDH1A1 (0.38) | KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL20111175 | 0.72 | POLB (0.36) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118708-A1 | CYCLIC COMPOUND | TLR4, TLR3, TLR9 | KDM4E 3638/4885MAPT 3713/4885NPC1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.